Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 9:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Moderate Liver Impairment Clear all
Completed Phase 2 Interventional Results available

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

NCT01830127
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Ribavirin, BI 207127 high dose, Faldaprevir, BI 207127 low dose
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
6
States / cities
La Mesa, California • San Diego, California • DeLand, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 4 Interventional

A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment

NCT02864199
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
12
States / cities
Birmingham, Alabama • Kansas City, Kansas • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

NCT06425198
View directory record Official record
Conditions
Hepatic Impairment, Healthy Participants
Interventions
BMS-986278
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
4
States / cities
Miami Lakes, Florida • Orlando, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 9, 2026, 9:11 AM EDT
Recruiting Phase 1 Interventional

Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

NCT05661461
View directory record Official record
Conditions
Tumor, Solid, Tumor, Advanced Solid Tumor
Interventions
nab-sirolimus
Drug
Lead sponsor
Aadi Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
San Antonio, Texas • West Valley City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function

NCT05098054
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
5
States / cities
Edgewater, Florida • Miami, Florida • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)

NCT06444204
View directory record Official record
Conditions
Hepatic Function Abnormal, Healthy Volunteers
Interventions
Rilzabrutinib
Drug
Lead sponsor
Principia Biopharma, a Sanofi Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects

NCT01860326
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
Alisporivir
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function

NCT06916078
View directory record Official record
Conditions
Liver Dysfunction, Healthy
Interventions
Lepodisiran
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment

NCT02581592
View directory record Official record
Conditions
Hepatic Impairment
Interventions
TD-4208
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects

NCT00805090
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hepatic Insufficiency, Healthy
Interventions
Sporanox, Diclofenac Sodium
Drug
Lead sponsor
Javelin Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of AGO178 in Participants With Liver Impairment

NCT01531309
View directory record Official record
Conditions
Hepatic Impairment
Interventions
AGO178
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Sep 9, 2026, 9:11 AM EDT
Recruiting Phase 1 Interventional

Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease

NCT06825559
View directory record Official record
Conditions
Cholestatic Liver Disease
Interventions
Saroglitazar Magnesium 1 mg
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 9, 2026, 9:11 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function

NCT07231991
View directory record Official record
Conditions
Healthy Participants
Interventions
vepdegestrant
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Miami, Florida • Miami Lakes, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 1 Interventional

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

NCT05718258
View directory record Official record
Conditions
Hepatic Function Abnormal
Interventions
Venglustat (GZ402671)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Rialto, California • Miami, Florida • Saint Paul, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2025 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function

NCT00416702
View directory record Official record
Conditions
Hepatic Insufficiency
Interventions
QAB149
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 9, 2008 · Synced Sep 9, 2026, 9:11 AM EDT
Terminated Phase 4 Interventional Results available

Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic Impairment

NCT03633227
View directory record Official record
Conditions
Liver Cirrhosis, Biliary
Interventions
Obeticholic Acid (OCA), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
11
States / cities
Rialto, California • Sacramento, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2022 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 1 Interventional

A Study to Learn How the Body Processes the Study Medicine Called Osivelotor (PF-07940367) in People With Loss of Liver Function

NCT06340347
View directory record Official record
Conditions
Liver Diseases
Interventions
Osivelotor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Lake Forest, California • Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 1 Interventional

Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function

NCT00118170
View directory record Official record
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
Interventions
sorafenib tosylate, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 6, 2013 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Results available

A Study of Saquinavir/Ritonavir in Liver-Impaired Patients With HIV Infection.

NCT00435929
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, saquinavir [Invirase]
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
5
States / cities
Chicago, Illinois • Somers Point, New Jersey • Voorhees Township, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 9, 2026, 9:11 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

NCT07343960
View directory record Official record
Conditions
Moderate Hepatic Impairment
Interventions
Capivasertib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Rialto, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function

NCT05835180
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis
Interventions
TVB-2640 - 50 mg
Drug
Lead sponsor
Sagimet Biosciences Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod

NCT04639115
View directory record Official record
Conditions
Liver Diseases, Digestive System Diseases
Interventions
Ozanimod
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435

NCT01046058
View directory record Official record
Conditions
Hepatitis C Virus
Interventions
TMC435
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
3
States / cities
Anaheim, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2013 · Synced Sep 9, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

NCT06535399
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
BMS-986369
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
3
States / cities
Chandler, Arizona • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 9, 2026, 9:11 AM EDT